In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 5, 1997, Pages 1124-1126

  Oakley, Karen L ^a   Moore, Caroline B ^a   Denning, David W ^a,b,c  

^a HOPE HOSPITAL   (United Kingdom)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [4 [4 [[5 (2,4 DIFLUOROPHENYL)TETRAHYDRO 5 (1H 1,2,4 TRIAZOL 1 YLMETHYL)FURAN 3 YL]METHOXY]PHENYL] 1 PIPERAZINYL] PHENYL] 2,4 DIHYDRO 2 (1 ETHYL 2 HYDROXYPROPYL) 3H 1,2,4 TRIAZOLE 3 ONE; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; ITRACONAZOLE; POSACONAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

AIDS RELATED COMPLEX; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CRYPTOCOCCUS; MINIMUM INHIBITORY CONCENTRATION; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL;

EID: 0030989041     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.5.1124     Document Type: Article

References (15)

1. Denning, D. W. 1996. Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 23:608-615.
2. Denning, D. W., S. E. Follansbee, M. Scolaro, S. Norris, H. Edelstein, and D. A. Stevens. 1991. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 324:654-662.
3. Denning, D. W., L. H. Hanson, A. M. Perlman, and D. A. Stevens. 1992. In vitro susceptibility and synergy studies of Apergillus species to conventional and new agents. Diagn. Microbiol. Infect. Dis. 15:21-34.
4. Denning, D. W., J. Y. Lee, J. S. Hostetler, P. Pappas, C. A. Kauffman, D. H. Dewsnup, J. N. Galgiani, J. R. Graybill, A. M. Sugar, A. Catanzaro, H. Gallis, J. R. Perfect, B. Dockery, W. E. Dismukes, and D. A. Stevens. 1994. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am. J. Med. 97:135-144.
5. Denning, D. W., S. A. Radford, K. L. Oakley, L. Hall, E. M. Johnson, and D. W. Warnock. Correlation between in vitro susceptibility testing of itraconazole and in vivo outcome of Aspergillus fumigatus infections. J. Antimicrob. Chemother., in press.
6. Espinel-Ingroff, A., M. Bartlett, R. Bowden, N. X. Chin, C. Cooper, Jr., A. Fothergill, M. R. McGinnis, P. Menezes, S. A. Messer, P. W. Nelson, F. C. Odds, L. Pasarell, J. Peter, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, G. S. Shankland, T. J. Walsh, and I. Weitzman. 1997. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J. Clin. Microbiol. 35:139-143.
7. Espinel-Ingroff, A., K. Dawson, M. A. Pfaller, E. Anaissie, B. Breslin, D. Dixon, A. Fothergill, V. Paetznick, J. Peter, M. Rinaldi, and T. Walsh. 1995. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob. Agents Chemother. 39:314-319.
8. Galgiani, J. N., and M. L. Lewis. 1997. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob. Agents Chemother. 41:180-183.
9. Groll, A. H., P. M. Shah, C. Mentzel, M. Schneider, G. Just-Nuebling, and K. Huebner. 1996. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect. 33:23-32.
10. Ng, T. T. C., G. D. Robson, and D. W. Denning. 1994. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 140:2475-2479.
11. Oakley, K. L., G. Morrissey, and D. W. Denning. 1996. Efficacy of SCH56592 in 2 immunocompromised murine models of invasive aspergillosis, abstr. F97, p. 116. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Pfaller, M. A., S. Messer, and R. N. Jones. 1997. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 41:233-235.
13. Radford, S. A., E. M. Johnson, D. W. Warnock, L. A. Hall, K. Oakley, and D. W. Denning. 1995. Development and evaluation of standardized methods for antifungal susceptibility testing of moulds. Presented at the PHLS 20th Annual Scientific Conference.
14. Roilides, E., A. Holmes, C. Blake, D. Venzon, P. A. Pizzo, and T. J. Walsh. 1994. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-γ. J. Infect. Dis. 170:894-899.
15. Roilides, E., T. Sein, A. Holmes, S. Chanock, C. Blake, P. A. Pizzo, and T. J. Walsh. 1995. Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J. Infect. Dis. 172:1028-1034.